Clinical trial
Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine
NCT00297856 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00297856 |
|---|---|
| Title | Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine |
| Official title | Open, Prospective Study of the Safety of GSK Biologicals' Boostrix® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) Administered to a Cohort of Adolescents in a US Health Maintenance Organization (HMO) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Diphtheria, Tetanus, Acellular Pertussis |
| Intervention type | Biological |
| Interventions | Boostrix®, Td (Tetanus diphtheria) vaccine |
| Enrollment | 10,000 |
| Start date | Mar 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Mar 1, 2006 |
| Last update posted | Jan 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: